Mobile Technology for Reducing and Preventing Adolescent Suicide

减少和预防青少年自杀的移动技术

• 批准号: 10154817
• 负责人: Seth Feuerstein
• 金额: $ 39.9万
• 依托单位: OUI THERAPEUTICS, INC
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-02-15 至 2022-08-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10154817
• 关键词: Adolescent; Adult; Aftercare; Age; Android; Anxiety; Apple; Caring; Cause of Death; Centers for Disease Control and Prevention (U.S.); Child; Clinical; Clinical Trials; Clinical Trials Cooperative Group; Cognitive Therapy; Data; Development; Devices; Feasibility Studies; Feedback; Feeling suicidal; Future; General Population; Goals; Heart Diseases; Hospitalization; Hospitals; Individual; Inpatients; Intervention; Life; Measures; Outcome; Participant; Patients; Phase; Population; Production; Publishing; Questionnaires; Randomized Controlled Trials; Research; Risk; Sampling; Site; Sleeplessness; Small Business Innovation Research Grant; Soldier; Suicide; Suicide attempt; Suicide prevention; Teenagers; Testing; Therapeutic; Therapy Clinical Trials; Time; United States; Visit; Work; Youth; acceptability and feasibility; adolescent suicide; age group; aged; base; cohort; commercialization; congenital anomaly; design; digital; effective intervention; effective therapy; efficacy testing; experience; feasibility testing; high risk; mobile application; mobile computing; mortality; open label; prevent; programs; reducing suicide; smartphone Application; substance use; suicidal; suicidal behavior; suicidal morbidity; suicidal risk; suicide rate; treatment as usual; trend; usability; young adult

ABSTRACT Suicide is a top two cause of death in the US for adolescents and suicide rates among youth have steadily increased. Despite this, there is a paucity of research on mobile technology designed to reduce suicide attempts among youth. In this Phase I SBIR application Oui Therapeutics, LLC proposes a project to: 1) Create a beta version of Aviva-Y for youth (ages 13 - 17); and 2) to test the feasibility and acceptability of the beta version of Aviva-Y in a single-group, open-label trial. Successful execution of the goals of this Phase I project will generate a version of Aviva-Y that is ready to be tested for efficacy with stabilized patients in a clinical trial. In the long term, this project will have a beneficial impact on the field of youth suicide prevention through the development of mobile technology designed to advance the delivery and dissemination of effective interventions.

摘要 自杀是美国青少年死亡的两大原因， 增加尽管如此，关于旨在减少自杀的移动的技术的研究仍然很少 年轻人的尝试。在第一阶段SBIR申请中，Oui Therapeutics，LLC提出了一个项目：1）创建 为青少年（13 - 17岁）提供Aviva-Y测试版; 2）测试测试版的可行性和可接受性 Aviva-Y的单组、开放标签试验。成功实现第一阶段项目的目标 将产生一个版本的Aviva-Y，准备在临床试验中测试稳定患者的疗效。 长远来说，这项计划会透过 发展移动的技术， 干预措施。